Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA

Neurology. 2006 Feb 14;66(3):313-8. doi: 10.1212/01.wnl.0000196476.10103.52.

Abstract

Background: An age bias may exist in the prescription of important secondary-preventive therapies in the elderly.

Objective: To evaluate patterns of drug prescription for cardiovascular prevention in the very elderly following hospitalization for an acute ischemic stroke or TIA.

Methods: The authors compared subjects ages > or = 80 with those < 80 in the California Acute Stroke Prototype Registry to evaluate the impact of age on receipt of secondary-prevention medications at the time of hospital discharge. Prespecified secondary-prevention drug classes studied were antithrombotics, lipid-lowering agents, and antihypertensives.

Results: Overall, there were 260 patients age > or = 80 and 534 age < 80 admitted with stroke or TIA during the study period. Patients > or = 80 years were less likely to receive actual treatment with antithrombotic medications (p = 0.002) and lipid-lowering medications (p = 0.005) but were more likely to receive antihypertensive medications (p = 0.0007) than their younger counterparts. With regard to optimal treatment (defined as receipt of, or a valid contraindication to, treatment in each category), those > or = 80 were equally likely to receive antithrombotic medications and lipid therapy but remained more likely to receive antihypertensive treatment (77.7 vs 67.0%; p = 0.0007). There were no differences in receipt of optimal combination therapy (defined as optimal treatment in all three therapeutic classes) between patient age groups, even when adjusted for medical history.

Conclusion: After hospitalization for stroke or TIA, no differences in overall optimal treatment prescription of secondary-prevention medications between patients ages > or = 80 and their younger counterparts were observed.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Age Factors
  • Aged*
  • Aged, 80 and over
  • Antihypertensive Agents / therapeutic use*
  • Cardiovascular Diseases / prevention & control*
  • Drug Utilization / statistics & numerical data
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Ischemic Attack, Transient / drug therapy*
  • Male
  • Middle Aged
  • Registries
  • Stroke / drug therapy*

Substances

  • Antihypertensive Agents
  • Fibrinolytic Agents
  • Hypolipidemic Agents